These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31987762)

  • 1. Unmasking catamenial hemoptysis in the era of CFTR modulator therapy.
    Montemayor K; Claudio AT; Carson S; Lechtzin N; Christianson MS; West NE
    J Cyst Fibros; 2020 Jul; 19(4):e25-e27. PubMed ID: 31987762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants.
    Mitchell E; Albon D
    Pediatr Pulmonol; 2024 Jul; 59(7):2009-2011. PubMed ID: 38607232
    [No Abstract]   [Full Text] [Related]  

  • 5. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant.
    Coman D; Vincent C; Huard G; Marleau D; Lavoie A; Hercun J
    J Cyst Fibros; 2024 May; 23(3):561-562. PubMed ID: 38000917
    [No Abstract]   [Full Text] [Related]  

  • 7. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
    Terlizzi V
    J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
    [No Abstract]   [Full Text] [Related]  

  • 8. Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis.
    Gonçalves Martynychen Canan M; Souza Sokoloski C; Rossetti Severo C; Zahi Rached S; Abensur Athanazio R
    Arch Bronconeumol; 2024 Aug; 60(8):526-528. PubMed ID: 38714384
    [No Abstract]   [Full Text] [Related]  

  • 9. CFTR modulator use in post lung transplant recipients.
    Benninger LA; Trillo C; Lascano J
    J Heart Lung Transplant; 2021 Dec; 40(12):1498-1501. PubMed ID: 34538541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
    Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG
    J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor.
    Middleton PG; Simmonds NJ
    Eur Respir J; 2024 Sep; 64(3):. PubMed ID: 39326905
    [No Abstract]   [Full Text] [Related]  

  • 12. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
    Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
    Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The march towards CFTR modulator access for all people with CF: The end of the beginning.
    VanDevanter DR
    J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
    [No Abstract]   [Full Text] [Related]  

  • 14. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis.
    Smith M; Ryan KJ; Gutierrez H; Sanchez LHG; Anderson JN; Acosta EP; Benner KW; Guimbellot JS
    J Cyst Fibros; 2022 Jan; 21(1):e8-e10. PubMed ID: 34130909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of severe pulmonary exacerbation in a young patient with cystic fibrosis in the era of CFTR modulators.
    Lanfranchi C; Rizza C; Russo MC; Borzani I; Angileri SA; Nazzari E; Alicandro G; Blasi F; Daccò V
    Int J Infect Dis; 2024 Oct; 147():107190. PubMed ID: 39053617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply to Piehler
    Duff AJA; Lee TWR
    Am J Respir Crit Care Med; 2024 Aug; 210(3):367. PubMed ID: 38843537
    [No Abstract]   [Full Text] [Related]  

  • 18. Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy.
    Piehler L; Thalemann R; Lehmann C; Stahl M; Mall MA; Graeber SY
    Am J Respir Crit Care Med; 2024 Aug; 210(3):365-367. PubMed ID: 38843542
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply: Reversal of structural abnormalities with elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: the earlier you start, the better the outcome will be!
    Chassagnon G; Burgel PR
    Eur Respir J; 2024 Sep; 64(3):. PubMed ID: 39326907
    [No Abstract]   [Full Text] [Related]  

  • 20. Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy.
    Fortner CN; Seguin JM; Kay DM
    J Cyst Fibros; 2021 Sep; 20(5):835-836. PubMed ID: 33846105
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.